Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAFE-IPF: Artesunate in Idiopathic Pulmonary Fibrosis
NCT05988463Phase 1Recruiting
- Start
- Aug 2026
- Primary completion
- Nov 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing Artesunate with Placebo (2 arms). Primary endpoint: Number of participants who experience treatment-related adverse events at 12 weeks. Started Aug 2026; status: recruiting.
02
Drugs
artesunate
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05988463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05988463.